Post on 28-Dec-2016
transcript
Life Science Competitiveness Indicators 1
Life Science Competitiveness Indicators
March 2015
Life Science Competitiveness Indicators 2
Preface
This report brings together in one place a set of competitiveness indicators covering a range of aspects of the life science environment in the UK and other countries. They are intended to give a broad understanding of the UK sector, and how it compares internationally.
The choice of these indicators was informed by Technical and Steering Groups made up of a range of life science sector stakeholders. These included representatives from trade associations, life science sector companies, research organisations, regulators and government bodies. Comparator countries have been selected on the basis of data availability, and advice from the Technical and Steering Groups as to the most appropriate comparators. In some instances where a comparison was considered desirable, it has not been possible as data for particular countries was not available or was not considered reliable.
There are a range of other UK specific data sources that were not used because internationally comparable data could not be identified. These limitations mean that, whilst this is the fullest picture we are currently able to provide, the set of indicators cannot be looked at in aggregate to provide an overall country ranking. Each indicator should be considered on its own merits and the caveats relating to data sources (which may be constantly updated) should be considered in each case. This report does not make any assessment of the relative importance of different factors for competitiveness, which is at least partly a subjective judgement.
For the most part, the data on which these indicators are based is drawn from already published data. Wherever possible a link is provided to the data, or to the publication from which the chart has been reproduced. In a few instances it has been necessary for data to be sourced commercially or obtained directly from the organisation holding it. In these cases the supplier is clearly credited against relevant charts. In cases where the data is from a proprietary source, we have not been able to reproduce the underlying data tables.
This is the first publication of these indicators. The intention is to further develop the indicator content and data sources for future publications.
We would like to thank all those who have contributed to these indicators, or supplied data for this publication.
Life Science Competitiveness Indicators 3
Table of contents
Overview: Performance of UK Life Science Sector and Contribution to UK Economy 4
Overview: Competitiveness of UK Life Science Environment 5
Indicators for UK industry 6
Chart 1A: Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations 7
Chart 1B: Number of people employed in manufacture of medical technology products 8
Chart 2A: Gross Value Added for pharmaceutical manufacturing in European competitor countries 9
Chart 2B: Gross Value Added for pharmaceutical manufacturing in UK 10
Chart 3A: Exports of pharmaceutical products 11
Chart 3B: Exports of medical technology products 12
Chart 4A: Imports of pharmaceutical products 13
Chart 4B: Imports of medical technology products 14
Chart 5A: Life sciences foreign direct investment projects 15
Chart 5B: Life sciences foreign direct investment capital expenditure 16
Chart 6A: Share of global life science Initial Public Offerings (IPOs) 2014 17
Chart 6B: Initial Public Offerings (IPOs) in life sciences amount raised in 2014 (where known) 18
Chart 7A: Private equity investment total investment 19
Chart 7B: Number of companies receiving private equity investment 20
Chart 8: Number of science graduates 21
Research and Development Indicators 22
Chart 9: Government spend on health research and development 23
Chart 10: 2013 non-industry spend on research and development 24
Chart 11: Pharmaceutical industry spend on research and development in the UK 25
Chart 12A: Share of life science academic citations 26
Chart 12B: Share of top 1% (most cited) life science citations 27
Regulatory Indicator 28
Chart 13: Instances where MHRA is in lead role in EU regulatory procedure 29
Clinical Research Indicators 30
Chart 14: Share of patients recruited to global studies (all trial phases) 31
Chart 15: Time from core package received to first patient enrolled in country (all trial phases) 32
Demand-side Indicators 33
Chart 16: Dashboard of NICE Technology Appraisal publication timeframes 34
Chart 17: Uptake of new medicines 35
Life Science Competitiveness Indicators 4
Overview: Performance of UK Life Science Sector and Contribution to UK Economy
Chart 5B: Life sciences foreign direct investment capital expenditure
2013
2012
2011
2010
2009
ItalySwitzerlandJapanFranceIrelandGermanyUKUnited States
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
Sp
end
in b
illio
ns o
f p
oun
ds
(b
n)
Source: fDi Markets, from The Financial Times Ltd.
Notes: Values are for the year that projects were announced. Data is in current prices.
Chart 1A: Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
2012
2011
2010
2009
2008
United KingdomNetherlandsItalyFranceSpainGermany
Num
ber
of
peo
ple
em
plo
yed
Source: Eurostat Data Explorer, Annual detailed enterprise statistics for industry, http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=en
Notes: Selected Category in NACE_R2 C21 Manufacture of basic pharmaceutical products andpharmaceutical preparations. Data not available for some countries in certain years.
Chart 1B: Number of people employed in manufacture of medical technology products
20132012
2011
2010
2009
0
50,000
100,000
150,000
200,000
250,000
Num
ber
of
peo
ple
em
plo
yed
SwitzerlandUnitedKingdom
NetherlandsItalyFranceSpainGermany
Source: Eurostat Data Explorer, Annual detailed enterprise statistics for industry, http://ec.europa.eu/eurostat/data/database
Notes: Categories in NACE_ R2 C266 Manufacture of irradiation, electromedical and electrotherapeutic equipment plus C325 Manufacture of medical and dental instruments and supplies. Data not available for some countries in certain years.
Chart 2B: Gross Value Added for pharmaceutical manufacturing in UK
0
5
10
15
201320122011201020092008200720062005
Gro
ss V
alue
Add
ed in
bill
ions
of p
ound
s (
bn)
Source: : UK data from ONS National Accounts, The Blue Book 2014 Edition dataset time series KKF7: mGDP manufacture of basic pharmaceutical products and pharmaceutical preparations http://www.ons.gov.uk/ ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.html
Notes: UK data (Chart 2B) has been taken from a separate source from the comparator countries as it is not currently available broken down at this level through Eurostat. The medical technology sector is defined by two three-digit categories (C266 and C325) and National Accounts data is not available at this level. Data is in current prices.
http://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.htmlhttp://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.htmlhttp://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=enhttp://ec.europa.eu/eurostat/data/database
Life Science Competitiveness Indicators 5
Overview: Competitiveness of UK Life Science Environment
Chart 8: Number of science graduates
2012
2011
2010
2009
2008
2012
2011
2010
2009
2008
0
25,000
50,000
75,000
100,000
250,000
300,000
Uni
ted
Sta
tes
Uni
ted
Kin
gdom
Sw
itzer
land
Spa
in
Net
herla
nds
Japa
n
Italy
Irela
nd
Ger
man
y
Fran
ce
Bel
gium
Num
ber
of
gra
dua
tes 200,000
Source: United Nations Educational, Scientific and Cultural Organisation (UNESCO) http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DS
Notes: Data not available for some countries in certain years.
Chart 12B: Share of top 1% (most cited) life science citations
2012
2011
2010
2009
2008
UnitedStates
RussianFederation
JapanItalyUnitedKingdom
FranceGermanyChinaCanada
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
55%
60%
65%
70%
Sha
re o
f ci
tatio
ns
Source: International Comparative Performance of the UK Research Base 2013 https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013
Notes: In cases of co-authorship, citations are allocated to all participating countries (so totals may be more than 100%).
Chart 9: Government spend on health research and development
USUKSpainJapanItalyGermany FranceBelgium
2012
2011
2010
2009
2008
Sp
end
in b
illio
ns o
f U
S d
olla
rs ($
bn)
2
005
pri
ces
0
1
2
3
4
25
30
35
40
Source: OECD Research & Development statistics http://stats.oecd.org/index.aspx?r=227797
Notes: Government budget appropriations or outlays on R&D in Health.
Chart 7A: Private equity investment total investment
2013
2012
2011
2010
2009
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
UKSwitzerlandSpainItalyIrelandGermanyFrance
Tota
l pri
vate
eq
uity
inve
stm
ent
in b
illio
ns o
f E
uro
s (
bn)
Source: European Private Equity & Venture Capital Association (EVCA) http://www.evca.eu/research/activity-data/annual-activity-statistics/]
Notes: Data is based on country of portfolio company. Data is in current prices.
http://www.evca.eu/research/activity-data/annual-activity-statistics/]http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DShttps://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013http://stats.oecd.org/index.aspx?r=227797
Life Science Competitiveness Indicators 6
Indicators for UK industry
Life Science Competitiveness Indicators 7
Chart 1A: Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
2012
2011
2010
2009
2008
United KingdomNetherlandsItalyFranceSpainGermany
Num
ber
of
peo
ple
em
plo
yed
Source: Eurostat Data Explorer, Annual detailed enterprise statistics for industry, http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=en
Notes: Selected Category in NACE_R2 C21 Manufacture of basic pharmaceutical products andpharmaceutical preparations. Data not available for some countries in certain years.
http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=sbs_na_ind_r2&lang=en
Life Science Competitiveness Indicators 8
Chart 1B: Number of people employed in manufacture of medical technology products
20132012
2011
2010
2009
0
50,000
100,000
150,000
200,000
250,000N
umb
er o
f p
eop
le e
mp
loye
d
SwitzerlandUnitedKingdom
NetherlandsItalyFranceSpainGermany
Source: Eurostat Data Explorer, Annual detailed enterprise statistics for industry, http://ec.europa.eu/eurostat/data/database
Notes: Categories in NACE_ R2 C266 Manufacture of irradiation, electromedical and electrotherapeutic equipment plus C325 Manufacture of medical and dental instruments and supplies. Data not available for some countries in certain years.
http://ec.europa.eu/eurostat/data/database
Life Science Competitiveness Indicators 9
Chart 2A: Gross Value Added for pharmaceutical manufacturing in European competitor countries
0
5.0
10.0
15.0
20.0
25.0
Netherlands
Italy
France
Spain
Germany
20122011201020092008200720062005
Gro
ss V
alue
ad
ded
in b
illio
ns o
f E
uro
s (
bn)
Source: Comparator countries data from Eurostat National Accounts data http://ec.europa.eu/eurostat/web/national-accounts/data/database
Notes: UK data (Chart 2B) has been taken from a separate source from the comparator countries as it is not currently available broken down at this level through Eurostat. The medical technology sector is defined by two three-digit categories (C266 and C325) and National Accounts data is not available at that level. Data is in current prices.
http://ec.europa.eu/eurostat/web/national-accounts/data/database
Life Science Competitiveness Indicators 10
Chart 2B: Gross Value Added for pharmaceutical manufacturing in UK
0
5
10
15
201320122011201020092008200720062005
Gro
ss V
alue
Ad
ded
in b
illio
ns o
f p
oun
ds
(b
n)
Source: UK data from ONS National Accounts, The Blue Book 2014 Edition dataset time series KKF7: mGDP manufacture of basic pharmaceutical products and pharmaceutical preparations http://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.html
Notes: UK data (Chart 2B) has been taken from a separate source from the comparator countries as it is not currently available broken down at this level through Eurostat. The medical technology sector is defined by two three-digit categories (C266 and C325) and National Accounts data is not available at this level. Data is in current prices.
http://www.ons.gov.uk/ons/rel/naa1-rd/united-kingdom-national-accounts/the-blue-book--2014-edition/index.html
Life Science Competitiveness Indicators 11
Chart 3A: Exports of pharmaceutical products
20132012
2011
2010
2009
0
10
20
30
40
50
60
70
USUK SwitzerlandSpainJapanItalyIrelandGermanyFranceBelgium
Exp
ort
s in
bill
ions
of
US
Do
llars
($b
n)
Source: UNCTAD STAT Data Center http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Notes: Categories used are [541] Medicinal and pharmaceutical products excluding 542, and [542] Medicaments including veterinary medicaments. Data is in current prices.
http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Life Science Competitiveness Indicators 12
Chart 3B: Exports of medical technology products
20132012
2011
2010
2009
USUK SwitzerlandSpainJapanItalyIrelandGermanyFranceBelgium
0
5
10
15
20
25
30
35E
xpo
rts
in b
illio
ns o
f U
S D
olla
rs ($
bn)
Source: UNCTAD STAT Data Center http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Notes: Categories used are [774] Electro-diagnostic apparatus for medical science etc. and [872] Instruments and appliances, n.e.s, for medical, etc. Data in current prices.
http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Life Science Competitiveness Indicators 13
Chart 4A: Imports of pharmaceutical products
20132012
2011
2010
2009
USUK SwitzerlandSpainJapanItalyIrelandGermanyFranceBelgium
0
10
20
30
40
50
60
70Im
po
rts
in b
illio
ns o
f U
S D
olla
rs ($
bn)
Source: UNCTAD STAT Data Center http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Notes: Categories used are [541] Medicinal and pharmaceutical products excluding 542, and [542] Medicaments including veterinary medicaments. Data is in current prices.
http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Life Science Competitiveness Indicators 14
Chart 4B: Imports of medical technology products
20132012
2011
2010
2009
USUK SwitzerlandSpainJapanItalyIrelandGermanyFranceBelgium
0
5
10
15
20
25
30Im
po
rts
in b
illio
ns o
f U
S D
olla
rs ($
bn)
Source: UNCTAD STAT Data Center http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Notes: Categories used are [774] Electro-diagnostic apparatus for medical science etc., and [872] Instruments and appliances, n.e.s, for medical, etc. Data is in current prices.
http://unctadstat.unctad.org/wds/ReportFolders/reportFolders.aspx?sCS_ChosenLang=en
Life Science Competitiveness Indicators 15
Chart 5A: Life sciences foreign direct investment projects
2013
2012
2011
2010
2009
0
20
40
60
80
100
120
ItalySwitzerlandJapanFranceIrelandGermanyUKUnited States
Num
ber
of
fore
ign
dire
ct in
vest
men
t p
roje
cts
Source: fDi Markets, from The Financial Times Ltd.
Notes: Numbers are for the year that projects were announced.
Life Science Competitiveness Indicators 16
Chart 5B: Life sciences foreign direct investment capital expenditure
2013
2012
2011
2010
2009
ItalySwitzerlandJapanFranceIrelandGermanyUKUnited States
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0S
pen
d in
bill
ions
of
po
und
s (
bn)
Source: fDi Markets, from The Financial Times Ltd
Notes: Values are for the year that projects were announced. Data is in current prices.
Life Science Competitiveness Indicators 17
Chart 6A: Share of global life science Initial Public Offerings (IPOs) 2014
US 71.7%
China Hong Kong 7.6%
China 6.7%
UK 4.1%
Sweden 2.7%
France 2.2%
Brazil 1.5%
New Zealand 1.0%
Other:Japan 0.9%South Korea 0.6%Singapore 0.5%Australia 0.2%Finland 0.2%Norway 0.1%
Source: S&P Capital IQ
Notes: Numbers refer to the country in which the IPO was launched, not the domicile of the IPOCompany.
Life Science Competitiveness Indicators 18
Chart 6B: Initial Public Offerings (IPOs) in life sciences amount raised in 2014 (where known)
Am
ount
rais
ed in
mill
ions
of p
ound
s (
m)
0
100
200
300
400
500
3,000
3,500
4,500
4,500
5,000
Norw
ay
Finlan
d
Austr
alia
Singa
pore
Sout
h Kor
eaJa
pan
New
Zeala
ndBr
azil
Franc
e
Swed
enUKChina
China
Hon
g Kon
gUS
Source: S&P Capital IQ
Notes: Values refer to the country in which the IPO was launched, not the domicile of the IPOCompany.
Life Science Competitiveness Indicators 19
Chart 7A: Private equity investment total investment
2013
2012
2011
2010
2009
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
UKSwitzerlandSpainItalyIrelandGermanyFrance
Tota
l pri
vate
eq
uity
inve
stm
ent
in b
illio
ns o
f E
uro
s (
bn)
Source: European Private Equity & Venture Capital Association (EVCA) http://www.evca.eu/research/activity-data/annual-activity-statistics/]
Notes: Data is based on country of portfolio company. Data is in current prices.
http://www.evca.eu/research/activity-data/annual-activity-statistics/]
Life Science Competitiveness Indicators 20
Chart 7B: Number of companies receiving private equity investment
2013
2012
2011
2010
2009
0
20
40
60
80
100
120
140
160
180
200
220N
umb
er o
f co
mp
anie
s
UKSwitzerlandSpain ItalyIrelandGermanyFrance
Source: European Private Equity & Venture Capital Association (EVCA) http://www.evca.eu/research/activity-data/annual-activity-statistics/]
Notes: Data is based on country of portfolio company.
http://www.evca.eu/research/activity-data/annual-activity-statistics/]
Life Science Competitiveness Indicators 21
Chart 8: Number of science graduates
2012
2011
2010
2009
2008
2012
2011
2010
2009
2008
0
25,000
50,000
75,000
100,000
250,000
300,000
Uni
ted
Sta
tes
Uni
ted
Kin
gdom
Sw
itzer
land
Spa
in
Net
herla
nds
Japa
n
Italy
Irela
nd
Ger
man
y
Fran
ce
Bel
gium
Num
ber
of
gra
dua
tes 200,000
Source: United Nations Educational, Scientific and Cultural Organisation (UNESCO) http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DS
Notes: Data not available for some countries in certain years.
http://data.uis.unesco.org/Index.aspx?DataSetCode=EDULIT_DS
Life Science Competitiveness Indicators 22
Research and Development Indicators
Life Science Competitiveness Indicators 23
Chart 9: Government spend on health research and development
USUKSpainJapanItalyGermany FranceBelgium
2012
2011
2010
2009
2008
Sp
end
in b
illio
ns o
f U
S d
olla
rs ($
bn)
2
005
pri
ces
0
1
2
3
4
25
30
35
40
Source: OECD Research & Development statistics http://stats.oecd.org/index.aspx?r=227797
Notes: Government budget appropriations or outlays on R&D in Health.
http://stats.oecd.org/index.aspx?r=227797
Life Science Competitiveness Indicators 24
Chart 10: 2013 non-industry spend on research and development
National Institute of Health and Research 959m
Association of Medical ResearchCharities Member Charities 1,294m
Medical Research Council 767m
Source: Association of Medical Research Charities http://www.amrc.org.uk/sites/default/files/doc_lib/AMRC-annual-review-2013-14.pdf
Notes: Expenditure by Medical Research Council and National Institute of Health Research will also be captured by Indicator 9.
http://www.amrc.org.uk/sites/default/files/doc_lib/AMRC-annual-review-2013-14.pdf
Life Science Competitiveness Indicators 25
Chart 11: Pharmaceutical industry spend on research and development in the UK
Sp
end
in b
illio
ns o
f p
oun
ds
(b
n)
0
1
2
3
4
5
201320122011201020092008200720062005200420032002
Source: ONS BERD survey 2013 http://www.ons.gov.uk/ons/rel/rdit1/bus-ent-res-and-dev/2013/stb-berd-2013.html
Notes: Data is not available for medical technology industry spend. Data is in current prices.
http://www.ons.gov.uk/ons/rel/rdit1/bus-ent-res-and-dev/2013/stb-berd-2013.html
Life Science Competitiveness Indicators 26
Chart 12A: Share of life science academic citations
2012
2011
2010
2009
2008
UnitedStates
RussianFederation
JapanItalyUnitedKingdom
FranceGermanyChinaCanada
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%S
hare
of
cita
tions
Source: International Comparative Performance of the UK Research Base 2013 https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013
https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013
Life Science Competitiveness Indicators 27
Chart 12B: Share of top 1% (most cited) life science citations
2012
2011
2010
2009
2008
UnitedStates
RussianFederation
JapanItalyUnitedKingdom
FranceGermanyChinaCanada
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
55%
60%
65%
70%S
hare
of
cita
tions
Source: International Comparative Performance of the UK Research Base 2013 https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013
Notes: In cases of co-authorship, citations are allocated to all participating countries (so totals may be more than 100%).
https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013
Life Science Competitiveness Indicators 28
Regulatory Indicator
Life Science Competitiveness Indicators 29
Chart 13: Instances where MHRA is in lead role in EU regulatory procedure
0
10%
20%
30%
40%
50%
60%
70%
UK Decentralised Procedures - Reference Member State
Scientific AdviceCo-ordinator
Centralised ProceduresRapporteur/Co-rapporteur
2014201320122011201020092008
Pro
po
rtio
n o
f to
tal c
ases
Source: Medicines and Healthcare Products Regulatory Agency
Notes: The chart illustrates the proportion of work the UK has undertaken in three key areas of European regulatory activity. As the work of the Medicines and Healthcare Products Regulatory Agency (MHRA) within the areas covered by these indicators is collaborative, no direct comparison with the other 27 Member States is made and the UKs position in the leading role is shown as a percentage of all work undertaken.
Each new medicinal product seeking approval in Europe through the Centralised Procedure has a Rapporteur and a co-Rapporteur appointed by the European Medicines Agency (EMA) to lead the assessment process. The Decentralised Procedure requires the applicant company to select a Reference Member State (RMS) to lead the assessment of the medicine during the procedure.
Life Science Competitiveness Indicators 30
Clinical Research Indicators
Life Science Competitiveness Indicators 31
Chart 14: Share of patients recruited to global studies (all trial phases)
2012
2011
2010
2009
2008
Czech RepublicPolandFranceGermanyUSUK
Sha
re o
f p
atie
nts
recr
uite
d g
lob
ally
0%
5%
10%
15%
20%
25%
30%
35%
40%
Source: This material is reproduced under a licence from CMR International.
Notes: You may not copy or re-distribute this material in whole or in part without the written consent of CMR International.
Life Science Competitiveness Indicators 32
Chart 15: Time from core package received to first patient enrolled in country (all trial phases)
2012
2011
2010
2009
2008
Czech RepublicPolandFranceGermanyUSUK
Day
s
0
50
100
150
200
250
300
Source: This material is reproduced under a licence from CMR International.
Notes: You may not copy or re-distribute this material in whole or in part without the written consent of CMR International. Core package received refers to receipt of final documentation relating to the clinical study by the local operating company or their representative.
Life Science Competitiveness Indicators 33
Demand-side Indicators
Life Science Competitiveness Indicators 34
Chart 16 Dashboard of NICE Technology Appraisal publication timeframes
Source: National Institute for Health and Care Excellence Technology Appraisal Programme
Notes: MA: Marketing AuthorisationACD: Appraisal Consultation DocumentFAD: Final Appraisal DeterminationDials address forecast and actual timeframes for different stages of the NICE Technology Appraisal process. Full details of the process, including descriptions of the separate stages can be found on the NICE website (http://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance). Red and Green zones on dials relate to whether milestones have been attained within existing targets for NICE performance.
http://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidancehttp://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidancehttp://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidancehttp://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance
Life Science Competitiveness Indicators 35
Chart 17 Uptake of new medicines
Year 1
11.4%
UK
up
take
per
hea
d/a
ll co
untr
y up
take
per
hea
d
0%
50%
100%
150%
200%
250%
300%
350%
Years from launch
Year 2
31.9%
Year 3
50.7%
Year 4
50.7%
Year 5
90.2%
Source: IMS Health, courtesy of the Office of Health Economics
Notes: The chart shows the per capita uptake of twenty-eight new medicines launched in the UK between 2007 to 2012 and approved (recommended or restricted) by NICE, compared to the average in a group of comparator countries (Australia, Austria, Belgium, Canada, Finland, France, Germany, Ireland, Italy, Japan, Netherlands, New Zealand, Spain, Sweden, Switzerland, and USA). The vertical lines represent uptake of the medicines in their 1st, 2nd etc. years after launch. Thus medicines launched in 2012 will only appear in the Year 1 from launch group, those launched in 2011 will appear in both the Year 1 from launch and Year 2 from launch groups and so on. The medicines launched in 2007 will appear in all five year groups.
The percentage number reported in each year is the median rate of uptake in the UK relative to the international average in that year; in other words half of the medicines have a higher UK relative rate of use, and half have a lower UK relative rate of use. A value below 100% means that the UK per capita consumption of the new medicine(s) is below the international average. For example, medicines in their 3rd year after launch (and subsequently approved by NICE) were used in the UK at a level which was on average 50.7% of the average usage in the comparator countries. Caution is required in the 5th year after launch as the median rate of uptake reported (90.2%) is based on only five data points (medicines) and is therefore highly sensitive to the choice of medicines included.
BIS/15/249
Life Science Competitiveness IndicatorsPrefaceTable of contentsOverview: Performance of UK Life Science Sector and Contribution to UK EconomyOverview: Competitiveness of UK Life Science EnvironmentIndicators for UK industryChart 1AChart 1BChart 2AChart 2BChart 3AChart 3BChart 4AChart 4BChart 5AChart 5BChart 6AChart 6BChart 7AChart 7BChart 8
Research and Development IndicatorsChart 9Chart 10Chart 11Chart 12AChart 12B
Regulatory IndicatorChart 13
Clinical Research IndicatorsChart 14Chart 15
Demand-side IndicatorsChart 16Chart 17